- TheFly reported on June 16 that Mizuho analyst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on the shares.
- The adjustment followed an update to the firm's valuation model after reviewing AMGN's first quarter results.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
(AMGN) Price Target Raised to $303 After Q1 Model Update Laiba Immad Wed, June 24, 2026 at 10:27 PM GMT+9 2 min read AMGN We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026 . (NASDAQ:AMGN) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Mizuho analyst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on the shares.
Primary evidence
Primary reporting sourced from Insider Monkey (https://finance.yahoo.com/healthcare/articles/amgen-inc-amgn-price-target-132701704.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant ANALYST RATING development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for $AMGN.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for $AMGN.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for $AMGN amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in $AMGN.
[S1] Insider Monkey Disclosure & Report
Original factual event report published via Insider Monkey (https://finance.yahoo.com/healthcare/articles/amgen-inc-amgn-price-target-132701704.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.
